Literature DB >> 29070502

Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.

Jason Weatherald1,2,3,4,5, Athénaïs Boucly6,2,3, Denis Chemla6,2,7, Laurent Savale6,2,3, Mingkai Peng8,5, Mitja Jevnikar6,2,3, Xavier Jaïs6,2,3, Yu Taniguchi6,2,3, Caroline O'Connell6,2,3, Florence Parent6,2,3, Caroline Sattler6,2,3, Philippe Hervé6,2,3, Gérald Simonneau6,2,3, David Montani6,2,3, Marc Humbert6,2,3, Yochai Adir9, Olivier Sitbon1,2,3.   

Abstract

BACKGROUND: Hemodynamic variables such as cardiac index and right atrial pressure have consistently been associated with survival in pulmonary arterial hypertension (PAH) at the time of diagnosis. Recent studies have suggested that pulmonary arterial compliance may also predict prognosis in PAH. The prognostic importance of hemodynamic values achieved after treatment initiation is less well established.
METHODS: Our objective was to evaluate the prognostic importance of clinical and hemodynamic variables during follow-up, including pulmonary arterial compliance, after initial management in PAH. We evaluated incident patients with idiopathic, drug- and toxin-induced, or heritable PAH enrolled in the French pulmonary hypertension registry between 2006 and 2016 who had a follow-up right-sided heart catheterization (RHC). The primary outcome was death or lung transplantation. We used stepwise Cox regression and the Kaplan-Meier method to assess variables obtained at baseline and at first follow-up RHC.
RESULTS: Of 981 patients, a primary outcome occurred in 331 patients (33.7%) over a median follow-up duration of 2.8 years (interquartile range, 1.1-4.6 years). In a multivariable model considering only baseline variables, no hemodynamic variables independently predicted prognosis. Median time to first follow-up RHC was 4.6 months (interquartile range, 3.7-7.8 months). At first follow-up RHC (n=763), New York Heart Association functional class, 6-minute walk distance, stroke volume index (SVI), and right atrial pressure were independently associated with death or lung transplantation, adjusted for age, sex, and type of PAH. Pulmonary arterial compliance did not independently predict outcomes at baseline or during follow-up. The adjusted hazard ratio for SVI was 1.28 (95% confidence interval, 1.11-1.49; P<0.01) per 10-mL/m2 decrease and for right atrial pressure was 1.05 (95% confidence interval, 1.02-1.09; P<0.01) per 1-mm Hg increase. Among patients who had 2 (n=355) or 3 (n=193) low-risk prognostic features at follow-up, including a cardiac index ≥2.5 L·min-1·m-2, 6-minute walk distance >440 m, and New York Heart Association class I or II functional class, lower SVI was still associated with higher rates of death or lung transplantation (P<0.01).
CONCLUSIONS: SVI and right atrial pressure were the hemodynamic variables that were independently associated with death or lung transplantation at first follow-up RHC after initial PAH treatment. These findings suggest that the SVI could be a more appropriate treatment target than cardiac index in PAH.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  follow-up studies; hemodynamics; hypertension, pulmonary; prognosis; pulmonary circulation; stroke volume; survival

Mesh:

Year:  2017        PMID: 29070502     DOI: 10.1161/CIRCULATIONAHA.117.029254

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

1.  Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.

Authors:  Lauren Rose; Kurt W Prins; Stephen L Archer; Marc Pritzker; E Kenneth Weir; Jeffrey R Misialek; Thenappan Thenappan
Journal:  J Heart Lung Transplant       Date:  2018-09-14       Impact factor: 10.247

2.  Nimura lecture: why are you evaluating RV function in patients with pulmonary arterial hypertension?

Authors:  Katsu Takenaka
Journal:  J Echocardiogr       Date:  2018-10-05

Review 3.  The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.

Authors:  Manreet Kanwar; Amresh Raina; Lisa Lohmueller; Jidapa Kraisangka; Raymond Benza
Journal:  Curr Hypertens Rep       Date:  2019-04-25       Impact factor: 5.369

4.  The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension.

Authors:  Marco Vicenzi; Sergio Caravita; Irene Rota; Rosa Casella; Gael Deboeck; Lorenzo Beretta; Andrea Lombi; Jean-Luc Vachiery
Journal:  PLoS One       Date:  2022-05-19       Impact factor: 3.752

5.  Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor.

Authors:  Raymond L Benza; Mark Doyle; David Lasorda; Kishan S Parikh; Priscilla Correa-Jaque; Nima Badie; Greg Ginn; Sophia Airhart; Veronica Franco; Manreet K Kanwar; Srinivas Murali; Amresh Raina; Rahul Agarwal; Sudarshan Rajagopal; Jason White; Robert Biederman
Journal:  Chest       Date:  2019-06-29       Impact factor: 9.410

Review 6.  Hemodynamics for the Heart Failure Clinician: A State-of-the-Art Review.

Authors:  Steven Hsu; James C Fang; Barry A Borlaug
Journal:  J Card Fail       Date:  2021-08-10       Impact factor: 5.712

7.  The isobaric pulmonary arterial compliance in pulmonary hypertension.

Authors:  Denis Chemla; Emmanuelle Berthelot; Jason Weatherald; Edmund M T Lau; Laurent Savale; Antoine Beurnier; David Montani; Olivier Sitbon; Pierre Attal; David Boulate; Patrick Assayag; Marc Humbert; Philippe Hervé
Journal:  ERJ Open Res       Date:  2021-05-31

Review 8.  Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression.

Authors:  Shu-Hao Wu; Yih-Jer Wu
Journal:  Acta Cardiol Sin       Date:  2022-03       Impact factor: 2.672

9.  Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?

Authors:  Ghaleb Khirfan; Manshi Li; Xiaofeng Wang; Raed A Dweik; Gustavo A Heresi; Adriano R Tonelli
Journal:  J Heart Lung Transplant       Date:  2021-04-02       Impact factor: 13.569

10.  Sex Differences in Portopulmonary Hypertension.

Authors:  Hilary M DuBrock; Rodrigo Cartin-Ceba; Richard N Channick; Steven M Kawut; Michael J Krowka
Journal:  Chest       Date:  2020-08-13       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.